ロード中...
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab (Cosentyx(®)), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). Subcutaneous secukinumab significantly improved the clinical signs and sympt...
保存先:
| 出版年: | Drugs |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6422944/ https://ncbi.nlm.nih.gov/pubmed/30793255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-019-01075-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|